SAN DIEGO - March 19, 2014 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB:AEMD), and its diagnostic subsidiary, Exosome Sciences, Inc. (ESI), announced today that researchers have isolated brainderived exosomes released into the bloodstream from aggressive brain tumors. Through the use of proprietary size exclusion/lectin/antibody-capture techniques, the Aethlon-ESI research team was able to identify, quantify, and characterize circulating Glioblastoma multiforme (GBM) exosomes, ... Read more

Montreal, Quebec, Canada - March 31, 2014 (Investorideas.com Biotech Newswire) Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer has issued a response to the recently released reports by the World Health Organization and the Pancreatic Cancer Action Network.


"We are very pleased with the progress we have made thus far in our efforts to re-domicile the ... Read more

Montreal, Quebec - April 7, 2014 (Investorideas.com Biotech Newswire) Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer today announced that it has resolved the two isomeric forms of its lead anticancer compound, Adva-27a, and as a result the specific activity of the drug candidate has increased 9.5-fold. Sunshine Biopharma had previously announced that the ... Read more

SAN DIEGO - April 9, 2014 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB:AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce.


In the coming months, we plan to initiate the first FDA approved study of Hemopurifier® therapy in the United States. Historically, U.S. clinical progression of extracorporeal devices directed toward a single disease indication has been a proven model for value creation.

Our clinical objectives are ... Read more

SAN DIEGO - April 22, 2014 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB:AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce.

[Investorideas.com Newswire]


When we initiated our first exosome research program, the medical community generally viewed these particles as nothing more than cellular debris with no biological function. In contrast, we believed that exosomes, also known as microvesicles or extracellular vesicles ... Read more

MONTREAL, QC - April 29, 2014 (Investorideas.com Biotech Newswire) Sunshine Biopharma, Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer today announced that it has entered into an Investment Agreement with Dutchess Opportunity Fund, II, LP ("Dutchess"). Dutchess has agreed to purchase up to $2.5 million of shares of Sunshine's Common Stock over a three-year commitment period. Under the ... Read more

SAN DIEGO - May 14, 2014 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB:AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce Investorideas.com Newswire The discovery that our Hemopurifer® captures tumor-secreted exosomes provides hope for a new therapeutic paradigm to augment cancer care. Yes, the same Hemopurifier® we are preparing to advance in a forthcoming FDA approved infectious disease study. In my last CEO note, I referenced a National ... Read more

SAN DIEGO - May 20, 2014 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB:AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, announced today that it has entered into a definitive agreement with DaVita Clinical Research (DCR) to provide clinical management services to support the forthcoming feasibility study of the Aethlon Hemopurifier®. The Hemopurifier is a first-in-class therapeutic ... Read more

SAN DIEGO - May 21, 2014 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB:AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, today announced high rapid virologic response (RVR) and sustained virologic response (SVR) rates in Hepatitis-C virus (HCV) infected individuals who were administered Hemopurifier® therapy. Investorideas.com Newswire The Aethlon Hemopurifier® is a first-in-class ... Read more

Montreal, Quebec, Canada - June 9, 2014 (Investorideas.com Biotech Newswire) Sunshine Biopharma, Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that Adva-27a, the Company’s flagship oncology drug candidate was featured in Global Markets Direct: Uterine Cancer - Pipeline Review, H1 2014 Report for its effectiveness against multidrug resistant uterine cancer cells in ... Read more

Point Roberts, WA, NEW YORK, NY - June 10, 2014 (Investorideas.com newswire) Investorideas.com, a global news source covering leading sectors including biotech and medical technology issues a Q&A interview with Mr. James A. Joyce ,Chairman and CEO of Aethlon Medical, Inc. (OTCBB:AEMD). Q: Investorideas.com How did Aethlon Medical become involved in cancer research? A: James A. Joyce, Chairman, CEO Several years ago, we made a bet that particles known as exosomes, were released by tumors ... Read more

New York, NY - June 16, 2014 (Investorideas.com Newswire) Investorideas.com, a leader in research for independent investors presents an exclusive Q&A interview with Mr. William J. Caragol, Chairman and Chief Executive Officer of PositiveID Corporation (OTCBB: PSID), a developer of biological detection and diagnostics solutions. Mr. Caragol discusses the current status and opportunities for its bio-threat detection technology and recently announced revenue guidance. Q: Investorideas.com On ... Read more

SAN DIEGO - June 17, 2014 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB:AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, announced today that the Company's Chairman and Chief Executive Officer, Jim Joyce, will present at The Wall Street Analyst Forum 25th Annual Institutional Investor Conference on Thursday, June 19th, at 12:05 PM EDT. Mr. Joyce's presentation will include an update ... Read more

SAN ANTONIO - June 19, 2014 (Investorideas.com Biotech Newswire) GenSpera, Inc. (OTCQB:GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, announces that Chairman and CEO, Craig Dionne, PhD, will deliver a company overview at the 2014 BIO International Convention, on Tuesday, June 24th, at 11:15 PDT, in San Diego, CA (http://mybio.org/search/all?terms=GenSpera). Dr. Dionne will give an update of the ongoing G- ... Read more

VANCOUVER - June 19, 2014 (Investorideas.com Mining stocks newswire) Further to its news release of May 14, 2014, Garibaldi Resources Corp. (the "Company" or "Garibaldi") is pleased to provide this progress report as drilling continues at the Silver Eagle target, Rodadero North in central Sonora State, Mexico. A fourth hole is now under way to test the geometry and dimensions of a promising high-grade, near-surface structure. Pending additional assay results are eagerly anticipated and will be ... Read more

SAN ANTONIO - June 23, 2014 (Investorideas.com Biotech Newswire) GenSpera, Inc. (OTCQB:GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, releases the updated corporate video explaining its lead drug candidate, G-202.


The video explains, "The thapsigargin plant, a weed that grows abundantly in the Mediterranean, kills by disruption of the calcium balance in cells, all cells. Now, Genspera has targeted its active ingredient thapsigargin, to kill ... Read more

SAN ANTONIO - June 24, 2014 (Investorideas.com Biotech Newswire) GenSpera, Inc. (OTCQB:GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, releases the 2014 BIO International corporate presentation. Chairman and CEO, Craig Dionne, PhD, presented the company overview and clinical trial updates for G-202 at the 2014 BIO International Convention, today, Tuesday, June 24th, at 11:15 PDT, in San Diego, CA.

Dr. Dionne presented interim results from the Phase Ib ... Read more

SAN DIEGO - June 25, 2014 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB:AEMD), the pioneer in creating medical devices that target unmet therapeutic needs in infectious disease and cancer, announced today that the presentation made by Company Chairman and CEO, Jim Joyce at The Wall Street Analyst Forum on June 19th, is now available at www.aethlonmedical.com. A link to Mr. Joyce's presentation, including both the audio and slide ... Read more

SAN ANTONIO - June 30, 2014 (Investorideas.com Biotech Newswire) GenSpera, Inc. (OTCQB:GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, releases the 2014 BIO International presentation by Chairman and CEO, Craig Dionne, PhD from the 2014 BIO International Convention held June 24th in San Diego, CA.

Dr. Dionne presented interim results from the Phase Ib and ongoing Phase II study for lead drug candidate, G-202.

Summary:

G-202 ... Read more

SAN ANTONIO - July 14, 2014 (Investorideas.com Biotech Newswire) GenSpera, Inc. (OTCQB:GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, announces that Kareg Corporation's Director of Research, Sheldon S. Traube, has issued the following research report on the company.

http://www.investorideas.com/CO/GNSZ/news/2014/07141.asp
  Read more

According to the report "Biomaterials Market by Material type, by Application, and by Region – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast (2015 – 2020)", published by Market Data Forecast, the global market is projected to reach USD 125.152 Billion by 2020, at a CAGR of 14% from 2015 to 2020.

For full report refer to http://www. ... Read more

New York, NY - Point Roberts, WA - April 14, 2014 (Investorideas.com Biotech Newswire) Investorideas.com, a global news source covering leading sectors including biotech and pharma, issues an exclusive Q&A interview with the CEO of Sunshine Biopharma Inc. ( OTCQB: SBFM ), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer.


Dr. Steve N. Slilaty, Chief Executive Officer of Sunshine ... Read more

International Pharmaceutical Conference and Expo

Description: 

With enthusiastic support of our Organizing Committee, we invite you to participate in the

Price and payment for exhibitors: 
Paid

The global licensing in pharma, biotech, and diagnostics segments are likely to attain renewed growth scope with several life science companies facilitating novel R&D initiatives favoring novelties in therapeutics and diagnostics for critical diseases. Such insightful market highlights along with other relevant market information have been thoroughly discussed in Market Research Hub’s (MRH) recently added research report titled, ' ... Read more